Intrahepatic Cholangiocarcinoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for intrahepatic cholangiocarcinoma. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
6
Active US patents
47/100
Avg vulnerability
—
Annual revenue covered

Originators in Intrahepatic Cholangiocarcinoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Taiho Oncology 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating intrahepatic cholangiocarcinoma. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
33
2
36
2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lytgobi
futibatinib
 Taiho Oncology 6 47 — 2033-02-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9108973 Lytgobi method of use 75 2033-02-13
9108973 Lytgobi method of use 70 2033-02-13
11833151 Lytgobi formulation 55 2039-11-05
11833151 Lytgobi formulation 55 2039-11-05
10434103 Lytgobi composition of matter 17 2036-03-31
10434103 Lytgobi composition of matter 12 2036-03-31

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10434103 Lytgobi composition of matter 12 2036-03-31
10434103 Lytgobi composition of matter 17 2036-03-31
11833151 Lytgobi formulation 55 2039-11-05
11833151 Lytgobi formulation 55 2039-11-05
9108973 Lytgobi method of use 70 2033-02-13
9108973 Lytgobi method of use 75 2033-02-13

Related